美敦力2亿美元收购疾病管理与患者监护服务提供商Cardiocom
2013-08-13 MedSci MedSci原创
2013年8月12日 ，世界最大医疗设备制造商美敦力公司(MDT)周一宣布，已同意以2亿美元收购疾病管理与患者监护服务提供商Cardiocom LLC。 美敦力表示，预计此项收购不会对其2014财年盈利产生影响。该公司表示，此项收购是其扩大对健康护理行业产品供应的计划之一部分。 Cardiocom专注于糖
2013年8月12日 ，世界最大医疗设备制造商美敦力公司(MDT)周一宣布，已同意以2亿美元收购疾病管理与患者监护服务提供商Cardiocom LLC。
美敦力表示，预计此项收购不会对其2014财年盈利产生影响。该公司表示，此项收购是其扩大对健康护理行业产品供应的计划之一部分。
Cardiocom专注于糖尿病和心血管疾病等重要疾病。其产品和服务包括远程监护和以患者为中心的软件。
Medtronic Advances Healthcare Services and Solutions Strategy with Acquisition of CardiocomCardiocom's Patient Management Offerings Reduce Healthcare Costs and Improve Care
MINNEAPOLIS - August 12, 2013 - Medtronic, Inc. (NYSE: MDT) today announced the closing of the acquisition of Cardiocom, a privately held developer and provider of integrated telehealth and patient services for the management of chronic diseases, in an all cash transaction valued at $200 million. Medtronic expects the net impact from this transaction to be neutral to fiscal year 2014 earnings and for this transaction to be consistent with the company's disciplined focus on long-term returns.This acquisition is in support of Medtronic's transition toward expanding the company's medical device product offerings to broader healthcare services and solutions, providing meaningful clinical and economic value for hospitals, physicians, patients and payers. The first area of focus for Medtronic will be in heart failure, where the addition of the Cardiocom technology and patient services to its product offerings will expand its reach to more patients across the heart failure care continuum.
"With broad healthcare reform initiatives focused on growing economic challenges, healthcare systems in every region of the world are striving to continuously improve outcomes, increase access, save cost, and improve the efficiency of healthcare delivery. The acquisition of Cardiocom is one step we are taking toward providing a combination of products and solutions that can help address those challenges," said Omar Ishrak, chairman and CEO of Medtronic. "With our first integration of this technology focused on heart failure, we will have the unique opportunity to combine our leading diagnostics, therapies and patient management solutions. This combination will strengthen our ability to partner with providers and payers to help them reduce cost and improve quality."
As the global medical technology leader in the chronic disease areas of cardiovascular, pain, and diabetes, Medtronic is extending its market-leading technology portfolio to include focused, complementary services and solutions that treat patients beyond those who solely rely on or need implanted medical devices. Cardiocom is specifically focused on a number of important challenging diseases, such as diabetes and cardiovascular disease, including heart failure and hypertension. Cardiocom's products and services include remote monitoring and patient-centered software to enable efficient care coordination and specialized telehealth nurse support. These integrated solutions are aimed at reporting real-time patient data and proactive patient intervention programs to payers and healthcare providers based on accepted guidelines and evidenced-based protocols, which can result in better outcomes at a lower cost.
"We are excited to announce the acquisition of Cardiocom, which provides Medtronic with a technology platform and services that allow physicians to better manage patients with chronic diseases," said Mike Genau, senior vice president and president of Medtronic's U.S. Region. "With the integration of Cardiocom, our portfolio of products and services will span the continuum of care for the management of heart failure, which affects an estimated 7.5 million people in the U.S. and is a significant burden to the healthcare system - representing 1.1 million hospital visits per year in the U.S. at a cost of $39 billion each year. We seek to reduce that burden on hospitals, physicians, payers and patients."
"We look forward to joining Medtronic as part of a combined portfolio of products and solutions that can positively impact outcomes for patients and bring value to our customers," said Daniel L. Cosentino, vice president and general manager of Cardiocom at Medtronic, and former CEO of Cardiocom. "The synergy between our technologies and Medtronic's large presence with hospitals, physicians and payers will dramatically increase our distribution channels for the Cardiocom patient management technologies and services. Our approach to care coordination and telehealth services has allowed customers to reduce the overall cost of care, primarily through reduced hospitalizations."
The Economic Burden of Chronic Disease
According to the Centers for Disease Control (CDC), 7 of 10 deaths in America are from chronic disease, with heart disease, stroke, cancer, diabetes and arthritis as the top five chronic diseases. Chronic diseases account for $3 of every $4 spent on health care or nearly $7,900 per every American.
To combat the costs of chronic disease, hospitals and physicians practices around the world are moving to initiate or improve value-based delivery models aimed at better managing and coordinating the care of high-cost, chronic disease patients. Hospitals are seeking to achieve more cost-effective care through the utilization of real-time patient data, earlier and more accurate interventions, and increased patient ownership and management of their disease. For example, one study of patients at the Veterans Health Administration showed the use of teleheath technology resulted in a 25 percent reduction in bed days of care and 20 percent reduction in number of admissions in heart failure1.
About Medtronic
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world.
小提示：本篇资讯需要登录阅读，点击跳转登录
版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
#美敦力#
40
#监护#
31
#疾病管理#
32